-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Diabetes is a metabolic disease, and the number of diabetic patients in China has been increasing in recent years
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
With the continuous growth of the number of patients, the diabetes drug market is expanding, so it has also attracted many pharmaceutical companies to compete for the layout
.
It is worth noting that, affected by this, in recent years, news of hypoglycemic drugs on the domestic market and over-reviews have also begun to spread
.
For example, in April, a number of pharmaceutical companies have announced that their hypoglycemic drugs have been approved and passed the consistency evaluation
.
On April 15, the NMPA released the drug approval information, which showed that Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
.
According to the data, metformin is the first-line drug for the treatment of type 2 diabetes.
According to Minet.
com data, in 2020, metformin has become the TOP1 non-insulin hypoglycemic drug in urban public hospitals, county-level public hospitals, urban community centers and township health centers in China.
varieties, with sales of more than 6.
2 billion yuan
.
It is worth noting that in recent years, Shandong New Era Pharmaceuticals has been increasing its layout in the field of diabetes medication, and has won miglitol tablets, glimepiride dripping pills and lipoic acid injection
.
In addition, the company's first insulin product, recombinant insulin glargine injection, has also been reported for production and is under review
.
On April 11, Yiling Pharmaceutical issued an announcement saying that the company received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Food and Drug Administration.
Quality and efficacy consistency evaluation
.
Among them, Gliquidone Tablets is a second-generation oral sulfonylurea hypoglycemic drug, which is a highly active islet β-cell-friendly agent.
It binds to specific receptors on the pancreatic β-cell membrane and can induce the production of an appropriate amount of insulin to reduce the blood sugar concentration.
.
Coincidentally, Lukang Pharmaceutical also announced on the 11th that its holding subsidiary Saite Company received the "Drug Supplementary Application Approval Document" (Approval No.
: 2022B01434) issued by the State Food and Drug Administration for Gliclazide sustained-release tablets.
The drug passed the quality and efficacy consistency evaluation of generic drugs
.
Gliclazide Modified Release Tablets (Gliclazide Modified Release Tablets) is a second-generation sulfonylurea drug, used as an oral diabetes treatment drug, mainly for non-islet-dependent diabetes mellitus when dietary therapy alone is not enough to control blood sugar.
The glycemic intensity is between tolbutamide and euglycemic
.
On April 7, Huadong Medicine announced that its holding subsidiary Doyle Biotech has obtained the final approval from the New Zealand Drug and Medical Device Safety Authority (Medsafe) and the Health and Disability Ethics Committee (HDEC) to carry out local injection of DR10624.
Phase I clinical trials for the treatment of type 2 diabetes, obesity, metabolic syndrome,
etc.
At present, there is no long-acting triple-target agonist drug targeting GLP-1R, GCGR and FGF21R at the same time in the world.
The DR10624 for injection has been approved for Phase I clinical trials in New Zealand, which is the first overseas approval of Doyle application for clinical trials
.
From the above point of view, in order to better seize the market, more and more companies are competing in the field of diabetes medication
.
The industry predicts that in the future, affected by the aging of the population, the improvement of living standards and unhealthy life>
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
According to new data released by the International Diabetes Federation (IDF) in 2021, the number of people with diabetes in China has reached 140 million
.
With the continuous growth of the number of patients, the diabetes drug market is expanding, so it has also attracted many pharmaceutical companies to compete for the layout
.
It is worth noting that, affected by this, in recent years, news of hypoglycemic drugs on the domestic market and over-reviews have also begun to spread
.
For example, in April, a number of pharmaceutical companies have announced that their hypoglycemic drugs have been approved and passed the consistency evaluation
.
On April 15, the NMPA released the drug approval information, which showed that Shandong New Era Pharmaceuticals' metformin hydrochloride sustained-release tablet category 4 generic marketing application was approved
.
According to the data, metformin is the first-line drug for the treatment of type 2 diabetes.
According to Minet.
com data, in 2020, metformin has become the TOP1 non-insulin hypoglycemic drug in urban public hospitals, county-level public hospitals, urban community centers and township health centers in China.
varieties, with sales of more than 6.
2 billion yuan
.
It is worth noting that in recent years, Shandong New Era Pharmaceuticals has been increasing its layout in the field of diabetes medication, and has won miglitol tablets, glimepiride dripping pills and lipoic acid injection
.
In addition, the company's first insulin product, recombinant insulin glargine injection, has also been reported for production and is under review
.
On April 11, Yiling Pharmaceutical issued an announcement saying that the company received the "Approval Notice for Supplementary Drug Application" approved and issued by the State Food and Drug Administration.
Quality and efficacy consistency evaluation
.
Among them, Gliquidone Tablets is a second-generation oral sulfonylurea hypoglycemic drug, which is a highly active islet β-cell-friendly agent.
It binds to specific receptors on the pancreatic β-cell membrane and can induce the production of an appropriate amount of insulin to reduce the blood sugar concentration.
.
Coincidentally, Lukang Pharmaceutical also announced on the 11th that its holding subsidiary Saite Company received the "Drug Supplementary Application Approval Document" (Approval No.
: 2022B01434) issued by the State Food and Drug Administration for Gliclazide sustained-release tablets.
The drug passed the quality and efficacy consistency evaluation of generic drugs
.
Gliclazide Modified Release Tablets (Gliclazide Modified Release Tablets) is a second-generation sulfonylurea drug, used as an oral diabetes treatment drug, mainly for non-islet-dependent diabetes mellitus when dietary therapy alone is not enough to control blood sugar.
The glycemic intensity is between tolbutamide and euglycemic
.
On April 7, Huadong Medicine announced that its holding subsidiary Doyle Biotech has obtained the final approval from the New Zealand Drug and Medical Device Safety Authority (Medsafe) and the Health and Disability Ethics Committee (HDEC) to carry out local injection of DR10624.
Phase I clinical trials for the treatment of type 2 diabetes, obesity, metabolic syndrome,
etc.
At present, there is no long-acting triple-target agonist drug targeting GLP-1R, GCGR and FGF21R at the same time in the world.
The DR10624 for injection has been approved for Phase I clinical trials in New Zealand, which is the first overseas approval of Doyle application for clinical trials
.
From the above point of view, in order to better seize the market, more and more companies are competing in the field of diabetes medication
.
The industry predicts that in the future, affected by the aging of the population, the improvement of living standards and unhealthy life>
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
